Compare Monster Beverage Corp (MNST) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Novo Nordisk A/S — how do they compare? Monster Beverage Corp trades at $94.48 (market cap $93.35B), while Novo Nordisk A/S trades at $49.32 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 2.4× Monster Beverage Corp's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| MNST | NVO | |
|---|---|---|
Market Cap | $93.35B | $220.53B |
Sector | Consumer Staples | Health |
52-Week High | $99.94 | $71.70 |
52-Week Low | $58.75 | $35.29 |
Enterprise Value | $91.65B | $239.49B |
Dividend Yield | — | 3.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
